J&J plant authorization clears way for big boost in U.S. COVID-19 shots

By , and
2 minute read
Register now for FREE unlimited access to Reuters.com

NEW YORK, March 23 (Reuters) - A large plant being used to manufacture Johnson & Johnson's (JNJ.N) COVID-19 vaccine was cleared by U.S. regulators on Tuesday, setting the stage for the weekly U.S. supply to surge more then 20 percent.

About 27 million COVID-19 vaccine doses will be allocated to U.S. states and other localities this week, including 4 million from J&J, White House spokeswoman Jen Psaki told reporters. read more That is the largest allocation yet, up from 22 million last week.

Earlier, the Indiana plant at which Catalent Inc (CTLT.N) is helping to manufacture the J&J vaccine received U.S. regulatory authorization, the companies said.

Register now for FREE unlimited access to Reuters.com

J&J's shipments had slowed considerably since the first week of the month, but the new authorization will enable it to ship out millions of doses.

J&J tapped contract manufacturers Catalent and Emergent BioSolutions Inc (EBS.N) to scale up production and meet its global supply targets. Catalent provides the final stage - called fill and finish - while Emergent makes the drug substance.

The U.S. Food and Drug Administration authorized the one-shot J&J vaccine in February, but only for its production facility in the Netherlands and a small fill-and-finish plant in the United States.

Based on that authorization, the company shipped nearly 4 million doses in the beginning of March. Shipments dropped sharply since then as J&J awaited the additional authorizations.

The company had previously promised to deliver 20 million vaccine doses by the end of March. read more

As of Tuesday morning, 82.7 million people in the United States had received at least one vaccine dose, around a quarter of the population, according to data from the Centers for Disease Control and Prevention.

Register now for FREE unlimited access to Reuters.com
Reporting by Caroline Humer

Our Standards: The Thomson Reuters Trust Principles.